Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Abid Chaudhry

Emergency Medicine Homestead, FL Medical Doctor

NPI 1902003635 CMS profile 1157666

1855 Ne 8Th St, Homestead, FL 33033

Open in the dashboard

General payments

$2,456

15 records reported · program years 2019–2025

Research payments

$1,234

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,837,756 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Abid Chaudhry of Homestead, FL is reported in the CMS Open Payments database as having received $2,456 across 15 general payments and $1,234 in research payments paid to them. Separately, studies naming them as principal investigator received $4,837,756 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2024 General $2,348 10
2024 Research $1,234 8
2022 General $30 1
2021 General $29 1
2019 General $30 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abid Chaudhry
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Abid Chaudhry were reported at $18. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Abid Chaudhry Emergency Medicine median Middle half National median
2019 $30 $51 $18–$128 $163
2020 $0 $29 $16–$99 $114
2021 $29 $40 $18–$124 $132
2022 $30 $49 $20–$134 $149
2023 $0 $51 $22–$142 $160
2024 $2,348 $52 $22–$150 $164
2025 $18 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Moderna TX, Inc. $2,144 8 payments
  2. Ethicon US, LLC $202 1 payment
  3. Organogenesis Inc. $30 1 payment
  4. Medtronic, Inc. $29 1 payment
  5. Zimmer Biomet Holdings, Inc. $19 1 payment
  6. Hologic, LLC $18 1 payment
  7. Genentech USA, Inc. $11 1 payment
  8. Pfizer Inc. $2 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,838 3 payments
  2. Food and Beverage $615 11 payments
  3. Education $2 1 payment
Products named General payments · program years 2019–2025
  1. STRATAFIX $202 1 payment
  2. Puraply $30 1 payment
  3. Sonicision $29 1 payment
  4. Lapidus Plate $19 1 payment
  5. Aptima $18 1 payment
  6. Xofluza $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi Pasteur Inc. $1,234 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

169

Median for Emergency Medicine: 88

Drug cost

$627

Median for Emergency Medicine: $590

Branded share of claims

21.9%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 25 $196
Azithromycin Generic 59 $189
Ibuprofen Generic 28 $88
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $79
Prednisone Generic 29 $45
Meloxicam Generic 16 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record